The Global CAR T-Cell Therapy market is expected to grow at a CAGR of 56.2% from 2018 to 2026.

The key vendors mentioned are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Bellicum Pharmaceuticals, Inc., Pfizer, Inc, Eureka Therapeutics, Autolus, TILT Biotherapeutics, and Fortress Biotech.

Chimeric Antigen Receptor (CAR) T Cell Therapy is a type of treatment in which patient T cells are changed in the laboratory to attack the cancer cells. In this therapy, T cells from patient body are isolated and inserted in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient’s cancer cells. CAR T-cell therapy uses patients own modified white blood cells to kill the cancer cells. CAR T-cell therapy is moreover a living drug and its benefits can last for many years. CAR T cell therapy is used in curing patients with breast cancer, pancreas cancer, colorectal cancer and various types of blood cancer. Factors such as technological advancement for advanced & reliable treatment for cancer, growing pharmaceutical industry, high prevalence of acute lymphoblastic lymphoma (ALL) and increase in the number of cell therapy clinical studies are fuelling the market growth. However, side-effects of CAR T-cell therapy and high cost of treatment are likely to hamper the market growth.

Access the complete report at:

Based on the application, diffuse large B-cell lymphoma is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults. This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age, though it can also occur in children and young adults in rare cases. DLBCL is an aggressive tumour which can arise in virtually any part of the body, and the first sign of this illness is typically the observation of a rapidly growing mass, sometimes associated with B symptoms of fever, weight loss, and night sweats.

Make an inquiry at:

Target Antigens Covered:
• CD20
• CD19
• HER2
• CD22
• GD2
• CD30
• HER1
• CD33

Products Covered:
• Allogeneic
• Autologous

Therapies Covered:
• Axicabtagene Ciloleucel (Yescarta)
• Tisagenlecleucel (Kymriah)

Applications Covered:
• Chronic Lymphocytic Leukemia
• Diffuse Large B-Cell Lymphoma
• Multiple Myeloma
• Acute Lymphoblastic Leukemia
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Glioblastoma
• Neuroblastoma
• Breast Cancer
• Sarcoma
• Acute Myeloid Leukemia
• Colorectal Cancer
• Pancreatic Cancer
• Hepatocellular Carcinoma
• Non-Hodgkin Leukemia
• Carcinoma

End Users Covered:
• Cancer Research Centers
• Hospitals
• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations

Regions Covered:
• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Learn more about Syngeneresearch here:

Key Questions Answered in this Report:
• How this market evolved since the year 2016
• Market size estimations, forecasts and CAGR for all the segments presented in the scope
• Key Market Developments and financials of the key players
• Opportunity Analysis for the new entrants
• SWOT Analysis of the key players
• Fastest growing markets analysed during the forecast period

Contact Info:
Name: Sadhana Shukla
Email: Send Email
Organization: Syngene Market Research Reports

Release ID: 88926735